{"id":"W3204497870","doi":"10.1016/j.annonc.2021.08.1158","title":"645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"LEO Pharma; Unicancer; EUSA Pharma; Ipsen; Cilag; Astellas Pharma; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; Eisai; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Double blind; Oncology; Cancer; Pathology; Androgen receptor; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001043584,0.001800522,0.002713255,0.000455197,0.0003890215,0.001064241,0.001049021,0.00138841,0.00912954],"category_scores_gemma":[0.0009681678,0.0008282322,0.001667382,0.0004473811,0.001063395,0.0009425392,0.0003527055,0.003603206,0.001410984],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006528492,"about_ca_system_score_gemma":0.001111683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001420749,"about_ca_topic_score_gemma":0.003228684,"domain_scores_codex":[0.9996754,0.0001435172,0.00001959177,0.00006694766,0.00002354166,0.00007100884],"domain_scores_gemma":[0.9995636,0.00009770858,0.00008214769,0.00003187833,0.00002679381,0.0001978658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9734958,0.007080583,0.0002942426,0.000501901,0.0008954298,0.00002651215,0.00002875289,0.0003839858,0.004009354,0.0001179317,0.0007007621,0.01246458],"study_design_scores_gemma":[0.947054,0.05054985,0.0007826663,0.00001493045,0.0003915398,0.00001828227,0.00001282515,0.0003603582,0.0003721201,0.00008721898,0.0003436699,0.00001257392],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842348,0.004169201,0.001083741,0.000710542,0.0007026817,0.003693216,0.001737792,0.0003548051,0.003313313],"genre_scores_gemma":[0.9830623,0.00323523,0.001880697,0.001283166,0.0004001187,0.002983208,0.001698287,0.00005200822,0.005405094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00912954,"threshold_uncertainty_score":0.03054142,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09777747175227228,"score_gpt":0.4186201061047073,"score_spread":0.320842634352435,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}